Zobrazeno 1 - 10
of 20
pro vyhledávání: '"L. L. Froelich"'
Autor:
P. MARDER, S. M. SPAETHE, L. L. FROELICH, B. J. CERIMELE, B. H. PETERSEN, T. TANNER, R. A. LUCAS
Publikováno v:
British Journal of Clinical Pharmacology. 42:457-464
Autor:
B. J. Cerimele, R. A. Lucas, S. M. Spaethe, P. Marder, L. L. Froelich, B. H. Petersen, T. Tanner
Publikováno v:
British Journal of Clinical Pharmacology. 42:457-464
1. The effects of orally administered LY293111 on ex vivo neutrophil Mac-1 upregulation were determined in a total of 24 healthy male subjects within three study periods. 2. In the first period, eight volunteers received 60 mg LY293111 or placebo thr
Publikováno v:
Journal of Medicinal Chemistry. 33:2807-2813
A series of lipophilic benzophenone dicarboxylic acid derivatives were found to inhibit the binding of the potent chemotaxin leukotriene B4 (LTB4) to its receptor on intact human neutrophils. Activity at the LTB4 receptor was determined by using a [3
Publikováno v:
Journal of Medicinal Chemistry. 33:2798-2807
A series of lipophilic benzophenone dicarboxylic acid derivatives was prepared which inhibited the binding of the potent chemotaxin leukotriene B4 to its receptor(s) on intact human neutrophils. With a radioligand-binding assay as a measure of recept
Autor:
W T, Jackson, L L, Froelich, R J, Boyd, J P, Schrementi, D L, Saussy, R M, Schultz, J S, Sawyer, M J, Sofia, D K, Herron, T, Goodson, D W, Snyder, P A, Pechous, S M, Spaethe, C R, Roman, J H, Fleisch
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 288(1)
The in vitro actions were investigated of LY293111, a potent and selective leukotriene B4 (LTB4) receptor antagonist, on human neutrophils, human blood fractions, guinea pig lung membranes, and guinea pig parenchymal and tracheal strips. The IC50 for
Autor:
M J, Sofia, P, Floreancig, N, Bach, S R, Baker, K, Nelson, J S, Sawyer, R, Baldwin, S L, Cockerham, J H, Fleisch, L L, Froelich, W T, Jackson, P, Marder, C R, Roman, D L, Saussy, S A, Silbaugh, S M, Spaethe, P W, Stengel
Publikováno v:
Advances in experimental medicine and biology.
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 263(3)
LY223982, (E)-5-(3-carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5- hexenyl)oxy)benzenepropanoic acid, is a newly discovered potent inhibitor of specific binding of leukotriene B4 (LTB4) to its receptor on human neutrophils. This study demonstrated that th
Publikováno v:
Eicosanoids. 5(1)
The utilization of a novel radioiodinated TXA2/PGH2 receptor antagonist, ISAP (7-[(1R,2S,3S,5R)-6,6-dimethyl-3(4- iodobenzenesulfonylamino)-bicyclo[3.1.1]-hept-2-yl]-5(Z)-heptenoic acid) to characterize TXA2/PGH2 receptors from guinea pig lung parenc
Publikováno v:
Receptor. 2(3)
A series of lipophilic benzophenone dicarboxylic acids have been shown to be inhibitors of the binding of LTB4 to its receptors on intact human neutrophils (Gapinski et al. (1990). Structure-activity relationships indicated that maximum activity was
Autor:
Morris JC; Department of Neurology, Washington University, St. Louis, MO, USA., Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, Wahlund LO, Dubois B
Publikováno v:
Journal of internal medicine [J Intern Med] 2014 Mar; Vol. 275 (3), pp. 204-13.